The Top 5 Biosimilar Articles for the Week of August 5

Number 5: July brought a lot of discussion regarding biosimilar policies, in both the US and abroad, as well as 3 highly anticipated FDA approvals.

Number 4: In addition to the overall 3.81% drug price inflation predicted in 2025, several originator biologics set to face biosimilar competition in the next few years are projected to increase their list prices, according to Vizient’s Pharmacy Market Outlook Report for Summer 2024.

Number 3: Value-driven health care strategies in Singapore’s public institutions have significantly increased biosimilar adoption, leading to reduced treatment costs and substantial savings for the health care system, according to a recent study.

Number 2: The variety of biologic medicines now available has helped countless patients deal with diseases for which traditional treatments were unsatisfactory. Individuals who have autoimmune diseases, cancer, and diabetes have benefited, as have those with previously untreatable genetic diseases. The most complex biologics first entered the market in the 1980s and 1990s, and for this reason, many of their patents are expiring. The concept of biosimilars was a rational idea that loosely mimicked the idea of generic drugs. However, because biologics are large, 3-dimensional, complex molecules, it took some time for regulatory agencies around the world to develop appropriate regulations.

Number 1: The FDA's new policy on glycan profiling of monoclonal antibodies (Mabs) receives praise and recommendations from Sarfaraz K. Niazi, PhD.

To read all of these articles and more, visit centerforbiosimilars.com.